Why were steroids previously contraindicated in Toxic Epidermal Necrolysis (TEN) and why are they now recommended for early use?

Historical Contraindication and Current Use of Steroids in TEN

Steroids were historically avoided in TEN due to theoretical concerns about increased infection risk and delayed re-epithelialization, but this was never based on high-quality evidence; current data suggests early, high-dose corticosteroids may reduce mortality when given within the first few days of disease onset, though the evidence remains limited and controversial.

Why Steroids Were Previously Contraindicated

The historical avoidance of corticosteroids in TEN stemmed from:

• Theoretical infection concerns: Opponents argued that systemic corticosteroids would increase sepsis risk in patients with extensive epidermal loss 1
• Lack of controlled evidence: Early case reports and clinical experience suggested potential harm, leading to widespread recommendations against their use 2
• Burn center influence: As TEN patients were often managed in burn units where steroids were avoided for thermal burns, this practice was extrapolated to TEN 3

Critical caveat: This contraindication was never supported by robust clinical trials—it was based primarily on theoretical concerns and anecdotal experience rather than systematic evidence 4.

Why Current Practice Has Shifted

The evolution toward steroid use is based on:

Key Evidence Supporting Early Steroid Use

Timing is critical: Proponents emphasize that high-dose corticosteroids must be given early in the disease course to inhibit the inflammatory cascade 1. The pathophysiology involves immune-mediated keratinocyte death, making early immunosuppression theoretically beneficial.

Retrospective data showing benefit:

• EuroSCAR analysis demonstrated lower mortality in German patients treated with corticosteroids versus supportive care alone 1
• High-dose pulse therapy studies (dexamethasone 1.5 mg/kg or methylprednisolone 1000 mg for 3 days) showed mortality rates below SCORTEN predictions 1
• A Chinese retrospective study of 70 patients found significantly lower actual versus expected mortality (SMR = 0.30, P = 0.0168), particularly with low-dose protocols 5

The Dosing and Timing Paradigm

Early, high-dose protocols appear most effective:

• IV dexamethasone 100 mg or 1.5 mg/kg daily for 3 days 1
• IV methylprednisolone 1000 mg for 3 consecutive days 1
• Treatment should begin within the first 24-48 hours of presentation

Important distinction: Low-dose or late-initiation steroids may be ineffective or harmful, explaining historical poor outcomes 5.

Current Guideline Position

The 2016 UK guidelines acknowledge the controversy but do not definitively recommend for or against steroids 1. The guideline states: "There is no conclusive evidence to demonstrate the benefit of any one intervention over conservative management" and emphasizes that "high-quality, multidisciplinary supportive care is the priority" 1.

However, the guidelines note:

• Ten published studies of corticosteroid treatment exist, all case series without randomized controlled trials 1
• Results are mixed, with some showing benefit and others showing no effect or harm
• No evidence demonstrates clear harm from corticosteroids when used appropriately 1

Practical Clinical Approach

When to Consider Steroids

Use early high-dose corticosteroids if:

• Patient presents within 24-48 hours of disease onset
• Diagnosis is confirmed (not SSSS or other mimicker)
• Patient is in a specialized unit with intensive monitoring capabilities
• No active systemic infection is present

Specific protocol:

1. IV methylprednisolone 1000 mg daily × 3 days, OR
2. IV dexamethasone 1.5 mg/kg daily × 3 days
3. Followed by rapid taper over 2-5 days

Critical Monitoring Requirements

• Infection surveillance: Daily skin and mucous membrane cultures 6
• Albumin monitoring: Lower albumin levels may require dose adjustment and increased antibiotic vigilance 5
• Concurrent antimicrobial therapy: 94.7% of patients receiving steroids required antibiotics in one series 5

Common Pitfalls to Avoid

1. Late initiation: Starting steroids after 72 hours is unlikely to be beneficial and may increase infection risk
2. Inadequate dosing: Low-dose protocols (e.g., prednisolone 1 mg/kg) appear less effective than pulse-dose regimens 5
3. Prolonged courses: Extended steroid therapy beyond 5-7 days increases infection risk without additional benefit
4. Using steroids as monotherapy: Must be combined with meticulous supportive care, wound management, and multidisciplinary monitoring 1, 6

The Bottom Line

The shift from contraindication to cautious use reflects recognition that the historical prohibition was not evidence-based. While definitive proof of benefit remains elusive, retrospective data suggests early, high-dose corticosteroids may reduce mortality when combined with excellent supportive care 5, 6. The key is early administration (within 24-48 hours), adequate dosing (pulse-dose regimens), and intensive monitoring in specialized units 7, 8.

The 2024 German S3 guideline and recent reviews continue to acknowledge this controversy, with practice varying by center and clinician experience 7, 9. In the absence of definitive RCT data, the decision should be made by experienced clinicians in specialized units, ideally within clinical registries to build better evidence 10, 1.